Paroxetine in social phobia/social anxiety disorder - Randomised, double-blind, placebo-controlled study

Background Preliminary studies have suggested that paroxetine may be effect ive in social phobia/social anxiety disorder. Aims To assess the efficacy and tolerability of paroxetine paroxetine in th e acute (12-week) treatment of social phobia. Method Two-hundred and ninety patients with social phobia were assigned ran domly to paroxetine (20-50 mg/day flexible dose) or placebo for 12 weeks of double-blind treatment. Primary efficacy outcomes were the Liebowitz Socia l Anxiety Scale (LSAS) total score (patient-rated) and the Clinical Global Impression (CGI) scale global improvement item. The secondary efficacy vari ables included CGI scale severity of illness score and the patient-rated So cial Avoidance and Distress Scale. Results Paroxetine produced a significantly greater reduction in LSAS total score (mean change from baseline: -29.4 v. -15.6; P less than or equal to 0.001) and a greater proportion of responders (score less than or equal to 2 on CGI global improvement) (65.7% v. 32.4%; P < 0.001) compared with plac ebo at the end of the 12-week study period. Both primary efficacy variables were statistically significant compared with placebo from week 4 onwards. Paroxetine was generally well tolerated. Conclusions Paroxetine is an effective, well-tolerated treatment for patien ts with social phobia. Declaration of interest Smith Kline Beecham Pharmaceuticals provided financ ial support for this study.